Middle East and Africa Virology Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Diagnostic Test, Viral Infection Controlling Techniques, Antiviral Therapeutics, and Interferons), Application (Skin and Soft Tissue Infections, Respiratory Tract Infections, GI Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infection, and Others), and End User (Hospitals, Diagnostic Laboratories, Pharmaceutical and Biotechnological Companies, and Research and Academic Institutes)
Market Introduction
The Middle East and Africa Virology market includes the consolidated markets for UAE, Saudi Arabia, South Africa, and rest of Middle East and Africa. The increasing viral outbreaks, increasing number of travelers in Middles East are driving the growth of virology market. in addition, increasing prevalence of HIV, and other epidemics such as Ebola in Africa creating opportunities for virology market. In addition, Saudi Arabia is one of the countries that could have a severe impact during the COVID-19 pandemic due to inbound travel activities such as the Hajj and Umrah. Saudi Arabia is expected to host up to 30 million pilgrims by 2030, which increases the risk of an epidemic and underlines the need for public health authorities to adapt to new ways of responding to outbreaks to prevent the spread of any upper respiratory tract viruses during these times. After discovering the MERS-CoV, the Saudi Ministry of Health (MoH) has promptly established the Saudi Center for Disease Control and Prevention (SCDC), which is now operational and in the frontline of the country's response to COVID-19. In addition, the Saudi MoH launched the National Health Laboratory (NHL), particularly providing advanced diagnostics to infectious diseases with high biocontainment laboratories. Additionally, the Saudi MoH has designated more than 25 regional hospitals for the isolation and treatment of MERS patients. These hospitals were well prepared to treat COVID-19 patients. In addition, Saudi Arabia is also one of the signatories on the WHO International Health Regulation and has been reporting on pandemic preparedness since and following the WHO policies on infection prevention and control. Thus, well-established healthcare infrastructure and well-structured pandemic preparedness policies are driving the virology market in coming years. Continuous requirement for cost-effective products is the major factor driving the growth of the MEA virology market.
Economic uncertainties and ongoing conflicts are worsening the condition in the region. For instance, countries like Syria, Libya, and Yemen are suffering violent conflict and cannot implement any public health measures. Iran was in a deep economic recession due to the US sanctions. Additionally, tightened financial condition is also decreasing the economic activities in the region. COVID-19 is the second coronavirus outbreak that has affected the Middle East, following the MERS-CoV reported in Saudi Arabia in 2012. Many countries are facing a shortage of testing kits in the region. Considering this, many government organizations are coming forward to help countries with a lack of resources. For instance, in September, The United Nations Children’s Fund (UNICEF) delivered around 115,800 Covid-19 test kits to help mitigate the Covid-19 pandemic in Nigeria. Also, the countries in the region are collaborating with international players to increase the testing capacity. In addition, the substantial direct health, and economic impacts of the Ebola epidemic in Guinea, Liberia, and Sierra Leone, diverted basic health care and government services to the outbreak, resulting in serious under-provision of health and social care. Economic growth also slowed significantly due to reduced financial investments and productivity levels during and after the outbreak. As per the Global Fund Organization, across 24 countries in Africa, only 11% of health facilities could conduct COVID-19 antigen rapid diagnostic tests, and only 8% could conduct PCR tests. Before the COVID-19, Lassa Fever was the priority, with the annual incidence of around 300,000-500,000 cases of Lassa Fever, with 5,000 related deaths in West Africa. However, COVID-19 has diverted all the rescores in handling the pandemic has impeded the growth of the other virus infections.
Get more information on this report :
Market Overview and Dynamics
The virology market in MEA is expected to grow from US$ 182.40 million in 2021 to US$ 221.46 million by 2028; it is estimated to grow at a CAGR of 2.8% from 2021 to 2028. Virology is among the significant sections of the healthcare system. It has an extensive application in vaccine development, diagnostics, treatment therapies, and others. The market players are constantly involved in product innovations and developments to sustain the competition in the market. They explore various scopes for product innovations. For instance, for COVID-19, market players are investing significantly in the development of vaccines, testing kits, and other related products and services. Below are a few of the market developments related to the virology market:
• In August 2021, the U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine known as the Pfizer-BioNTech COVID-19 Vaccine. It will be marketed as ComiRNAty (Koe-mir’-na-tee). The vaccine is intended to prevent COVID-19 disease in individuals aged 16 years and above. It is also available under emergency use authorization (EUA).
• In April 2021, CerTest Biotec launched its CE-marked COVID-19 diagnostic test for the BD MAX System.
• In May 2020, Bio-Rad received FDA approval for emergency use authorization for the COVID-19 total antibody test.
• In May 2020, Aalto Bio Reagents launched New Recombinant Eukaryotic SARS-CoV-2 S1-S2 Spike Proteins.
Thus, such active participation of the market players by product innovations and favourable governments support is expected to bolster the growth of the MEA virology market.
Key Market Segments
The MEA virology market is segmented on the bases of type, application, end user, and country. Based on type, the market is segmented into diagnostic test, viral infection controlling techniques, antiviral therapeutics, and interferons. The antiviral therapeutics segment dominated the market in 2020, and viral infection controlling techniques segment is expected to be the fastest growing during the forecast period. The diagnostic test segment is further categorized into DNA virus testing, RNA virus testing, others. Similarly, the viral infection controlling techniques is bifurcated into active prophylaxis, and passive prophylaxis. Likewise, the antiviral therapeutics segmented is categorized into virucidal agents, antiviral agents, immunomodulators, and interferons. On the basis of application, the virology market is segmented into skin and soft tissue infections, respiratory tract infections, GI tract infections, sexually transmitted diseases, urinary tract infections, and others. The respiratory tract infections segment dominated the market in 2020, and is expected to be the fastest growing during the forecast period. On the basis of end user, the virology market is segmented into hospitals, diagnostic laboratories, pharmaceutical and biotechnological companies, and research and academic institutes. The hospitals segment dominated the market in 2020, and diagnostic laboratories segment is expected to be the fastest growing during the forecast period.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the virology market in MEA are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; AbbVie Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline Plc; Illumina, Inc.; Johnson and Johnson Services, Inc.; QIAGEN; Siemens AG; and Thermo Fisher Scientific Inc. are among others.
Reasons to buy report
- To understand the MEA virology market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for MEA virology market
- Efficiently plan M&A and partnership deals in MEA virology market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form MEA virology market
- Obtain market revenue forecast for market by various segments from 2021-2028 in MEA region.
MEA Virology Market Segmentation
MEA Virology Market -By Type
- Diagnostic Test
- DNA Virus Testing
- RNA Virus Testing
- Others
- Viral Infection Controlling Techniques
- Active Prophylaxis
- Passive Prophylaxis
- Antiviral Therapeutics
- Virucidal Agents
- Antiviral Agents
- Immunomodulators
- Interferons
MEA Virology Market -By Application
- Skin and Soft Tissue Infections
- Respiratory Tract Infections
- GI Tract Infections
- Sexually Transmitted Diseases
- Urinary Tract Infections
- Others
MEA Virology Market -By End User
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical and Biotechnological Companies
- Research and Academic Institutes
MEA Virology Market -By Country
- UAE
- Saudi Arabia
- South Africa
- Rest of MEA
MEA Virology Market -Company Profiles
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Virology Market – By Type
1.3.2 MEA Virology Market – By Application
1.3.3 MEA Virology Market – By End User
1.3.4 MEA Virology Market– By Country
2. MEA Virology Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Virology Market– Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Experts Opinion
5. MEA Virology Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Viral Infectious Diseases
5.1.2 Increasing Product Launches
5.2 Market Restraints
5.2.1 Availability of Alternative Products and High Price of Production of Products
5.3 Market Opportunities
5.3.1 Major Growth Potential in Emerging Economies
5.4 Future Trends
5.4.1 Continuous Requirement for Cost-Effective Products
5.5 Impact Analysis
6. Virology Market– MEA Analysis
6.1 MEA Virology Market Revenue Forecast and Analysis
7. MEA Virology Market Analysis – By Type
7.1 Overview
7.2 MEA Virology Market Revenue Share, by Type (2021 and 2028)
7.3 Diagnostic Test
7.3.1 Overview
7.3.2 Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Deoxyribonucleic Acid (DNA) Virus Testing
7.3.2.1.1 Overview
7.3.2.1.2 DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Ribonucleic Acid (RNA) Virus Testing
7.3.2.2.1 Overview
7.3.2.2.2 RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Others
7.3.2.3.1 Overview
7.3.2.3.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Viral Infection Controlling Techniques
7.4.1 Overview
7.4.2 Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Active Prophylaxis
7.4.2.1.1 Overview
7.4.2.1.2 Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Passive Prophylaxis
7.4.2.2.1 Overview
7.4.2.2.2 Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Antiviral Therapeutics
7.5.1 Overview
7.5.2 Antiviral Therapeutics: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Virucidal Agents
7.5.2.1.1 Overview
7.5.2.1.2 Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Antiviral Agents
7.5.2.2.1 Overview
7.5.2.2.2 Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Immunomodulators
7.5.2.3.1 Overview
7.5.2.3.2 Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Interferons
7.6.1 Overview
7.6.2 Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8. MEA Virology Market Analysis – By Application
8.1 Overview
8.2 MEA Virology Market, by Application 2021 & 2028 (%)
8.3 Skin and Soft Tissue Infections
8.3.1 Overview
8.3.2 Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Respiratory Tract Infections
8.4.1 Overview
8.4.2 Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.5 GI Tract Infections
8.5.1 Overview
8.5.2 GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Sexually Transmitted Diseases
8.6.1 Overview
8.6.2 Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Urinary Tract Infections
8.7.1 Overview
8.7.2 Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9. MEA Virology Market Analysis – By End User
9.1 Overview
9.2 MEA Virology Market Revenue Share, by End User (2021 and 2028)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Pharmaceutical and Biotechnological Companies
9.5.1 Overview
9.5.2 Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Research and Academic Institutes
9.6.1 Overview
9.6.2 Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
10. MEA Virology Market – Country Analysis
10.1.1 Overview
10.1.2 Middle East & Africa: Virology Market, by Country, 2021 & 2028 (%)
10.1.2.1 Saudi Arabia: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 Saudi Arabia: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.2 Saudi Arabia Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.2.1 Saudi Arabia: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.1.2.2 Saudi Arabia: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.1.2.3 Saudi Arabia: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.1.3 Saudi Arabia: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.4 Saudi Arabia: Virology Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.2.2 UAE: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 UAE: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.2 UAE Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.2.1 UAE: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.2.2.2 UAE: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.2.2.3 UAE: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.2.3 UAE: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.4 UAE: Virology Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.2.3 South Africa: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 South Africa: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.2 South Africa Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.2.1 South Africa: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.3.2.2 South Africa: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.3.2.3 South Africa: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.3.3 South Africa: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.4 South Africa: Virology Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.2.4 Rest of Middle East and Africa: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.1 Rest of Middle East and Africa: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.2 Rest of Middle East and Africa Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.2.1 Rest of Middle East and Africa: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.4.2.2 Rest of Middle East and Africa: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.4.2.3 Rest of Middle East and Africa: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.4.3 Rest of Middle East and Africa: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.4 Rest of Middle East and Africa: Virology Market, by End User – Revenue and Forecast to 2028 (USD Million)
11. Impact of COVID-19 Pandemic on MEA Virology Market
11.1 Overview
12. MEA Virology Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Abbott
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Johnson and Johnson Services, Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 F. HOFFMANN-LA ROCHE LTD.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 QIAGEN
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Illumina, Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 GlaxoSmithKline Plc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 AbbVie Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Gilead Sciences, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. MEA Virology Market Revenue and Forecast to 2028 (US$ Million)
Table 2. Saudi Arabia Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 3. Saudi Arabia Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 4. Saudi Arabia Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 5. Saudi Arabia Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 6. Saudi Arabia: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 7. Saudi Arabia: Virology Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 8. UAE Virology Market, By Type – Revenue and Forecast to 2028(USD Million)
Table 9. UAE Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 10. UAE Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 11. UAE Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 12. UAE: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 13. UAE: Virology Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 14. South Africa Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 15. South Africa Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 16. South Africa Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 17. South Africa Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 18. South Africa: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 19. South Africa: Virology Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 20. Rest of Middle East and Africa Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 21. Rest of Middle East and Africa Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 22. Rest of Middle East and Africa Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 23. Rest of Middle East and Africa Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 24. Rest of Middle East and Africa: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 25. Rest of Middle East and Africa: Virology Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 26. Organic Developments Done by Companies
Table 27. Inorganic Developments Done by Companies
Table 28. Glossary of Terms, Virology Market
LIST OF FIGURES
Figure 1. MEA Virology Market Segmentation
Figure 2. MEA Virology Segmentation, By Country
Figure 3. MEA Virology Market Overview
Figure 4. Antiviral Therapeutics Held the Largest Share of the Type Segment in MEA Virology Market
Figure 5. Respiratory Tract Infections Held the Largest Share of the Application Segment in MEA Virology Market
Figure 6. South Africa to Show Significant Growth During Forecast Period
Figure 7. MEA PEST Analysis
Figure 8. MEA Virology Market: Impact Analysis of Drivers and Restraints
Figure 9. MEA Virology Market– Revenue Forecast and Analysis – 2019- 2028
Figure 10. MEA Virology Market Revenue Share, by Type (2021 and 2028)
Figure 11. MEA Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. MEA DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. MEA RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. MEA Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. MEA Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. MEA Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. MEA Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. MEA Antiviral Therapeutics: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. MEA Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. MEA Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. MEA Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. MEA Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. MEA Virology Market, by Application 2021 & 2028 (%)
Figure 24. MEA Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. MEA Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. MEA GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. MEA Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. MEA Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. MEA Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. MEA Virology Market Revenue Share, by End User (2021 and 2028)
Figure 31. Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Middle East and Africa: Virology Market, by Key Country – Revenue (2021) (USD Million)
Figure 36. Middle East & Africa: Virology Treatment Market, by Country, 2021 & 2028 (%)
Figure 37. Saudi Arabia: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. UAE: Virology Treatment Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. South Africa: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 40. Rest of Middle East and Africa: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 41. Impact of COVID-19 Pandemic on Virology Market in MEA Countries
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the MEA Virology market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the MEA Virology market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the Virology market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution